Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes

被引：13

作者：

Yaribeygi, Habib ^{[1
]}

Atkin, Stephen L. ^{[2
]}

Sahebkar, Amirhossein ^{[3
,4
,5
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Chron Kidney Dis Res Ctr, Tehran, Iran

[2] Weill Cornell Med Qatar, Doha, Qatar

[3] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran

[4] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Razavi Khorasan, Iran

[5] Mashhad Univ Med Sci, Sch Pharm, Mashhad, Razavi Khorasan, Iran

来源：

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS | 2019年 / 13卷 / 02期

关键词：

Sodium-glucose co-transporter inhibitors; Oxidative stress; Diabetes mellitus; Hypertension; INADEQUATE GLYCEMIC CONTROL; COTRANSPORTER; 2; INHIBITORS; DOUBLE-BLIND; OXIDATIVE STRESS; NITRIC-OXIDE; ADD-ON; GLOMERULAR HYPERFILTRATION; RENAL DYSFUNCTION; NERVOUS-SYSTEM; TYPE-2;

D O I：

10.1016/j.dsx.2019.03.031

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetes mellitus prevalence is increasing worldwide leading to increased morbidity and mortality through diabetes related microvascular and macrovascular disease. The treatment of hypertension has been shown to be a major therapeutic intervention for the prevention of cardiovascular events and other diabetes related complications in diabetes. Sodium-glucose co-transporter inhibitors (SGLT2i) are newly introduced anti-diabetes drugs that lower blood glucose by the inhibition of glucose reuptake and the induction of glycosuria. However, there is increasing evidence showing their cardiovascular benefit beyond the improvement of glycemic control. Here we review the latest findings on the effect of SGLT2i on blood pressure in diabetes. (c) 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.

引用

页码：1679 / 1683

页数：5

共 50 条

[31] Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases
Layton, A. T.
Vallon, V.
ACTA PHYSIOLOGICA, 2018, 222 (04)
[32] SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond
Tuttle, Katherine R.
LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (01): : 3 - 5
[33] SGLT2 Inhibition: A Novel Prospective Strategy in Treatment of Diabetes Mellitus
Deshmukh, Aaishwarya B.
Patel, Maharshi C.
Mishra, Bharat
RENAL FAILURE, 2013, 35 (04) : 566 - 572
[34] SGLT2 Inhibition, Visceral Adiposity, Weight, and Type 2 Diabetes Mellitus
Carbone, Salvatore
O'Keefe, James H.
Lavie, Carl J.
OBESITY, 2020, 28 (07) : 1173 - 1173
[35] SGLT2 inhibition: an effective therapeutic approach in the treatment of diabetes mellitus?
Rudofsky, G.
Ruessmann, H. -J.
Siegmund, T.
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (22) : 1172 - 1177
[36] SGLT2 inhibition with dapagliflozin A novel approach for the management of type 2 diabetes
Kilov, Gary
Leow, Stephen
Thomas, Merlin
AUSTRALIAN FAMILY PHYSICIAN, 2013, 42 (10) : 706 - 710
[37] Inhibition of SGLT2: A Novel Strategy for Treatment of Type 2 Diabetes Mellitus
Pfister, M.
Whaley, J. M.
Zhang, L.
List, J. F.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (04) : 621 - 625
[38] Multi-omic Analysis Of The Effect Of SGLT2 Inhibition On Blood Pressure In Dahl SS Rats
Kravtsova, Olha
Billing, Anja M.
Upadhyay, Gunjan
Levchenko, Vladislav
Liu, Ruisheng
Rieg, Timo
Rinschen, Markus M.
Halade, Ganesh V.
Staruschenko, Alexander
HYPERTENSION, 2023, 80
[39] Renal Effects of Antisense-Mediated Inhibition of SGLT2
van Meer, Leonie
Moerland, Matthijs
van Dongen, Marloes
Goulouze, Bas
de Kam, Marieke
Klaassen, Erica
Cohen, Adam
Burggraaf, Jacobus
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 359 (02): : 280 - 289
[40] Understanding the Benefits of SGLT2 Inhibition
Vega, Rick B.
JACC-BASIC TO TRANSLATIONAL SCIENCE, 2023, 8 (09): : 1098 - 1099

← 1 2 3 4 5 →